Additionally, a review by Gao et al. (2024) [35] focused on functional abilities and quality of life, showing that SGLT2 inhibitors lead to higher KCCQ scores and improved exercise capacity in HF patients. The gene discussed is SLC5A2; the disease is hydrops fetalis.